News
LIFE
1.595
-0.31%
-0.005
Weekly Report: what happened at LIFE last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at LIFE last week (0408-0412)?
Weekly Report · 04/15 10:12
12 Health Care Stocks Moving In Tuesday's After-Market Session
Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. ATyr Pharma shares rose 10.45% and Corvus Pharma shares increased by 7.36%. Apyx Medical shares declined by 6.1% during the session.
Benzinga · 04/09 20:31
Weekly Report: what happened at LIFE last week (0401-0405)?
Weekly Report · 04/08 10:15
Weekly Report: what happened at LIFE last week (0325-0329)?
Weekly Report · 04/01 10:14
aTyr Pharma to Participate in April Investor Conferences
ATyr Pharma, Inc. Will participate in two upcoming investor conferences scheduled to take place in April 2024. The company is a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines. The company will be in San Diego.
Barchart · 04/01 07:00
Weekly Report: what happened at LIFE last week (0318-0322)?
Weekly Report · 03/25 10:16
WW, ATNM and XTIA are among pre market gainers
On the Move WW, ATNM and XTIA are among pre market gainers. Fusion Pharmaceuticals (FUSN) will buy Fusion pharmaceuticals for $2B. SCWorx (WORX) is up 18%. National Cinemedia (NCMI) gains 25%.
Seeking Alpha · 03/19 12:04
Weekly Report: what happened at LIFE last week (0311-0315)?
Weekly Report · 03/18 10:15
3 Best Stocks to Buy Now, 3/18/2024, According to Top Analysts 
According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well. Jabil, Applied Digital Corporation and Life Pharma are among today's top stock picks, according to analysts. TipRanks ranks financial analysts according to the accuracy of their ratings.
TipRanks · 03/18 06:05
aTyr Pharma Is Maintained at Outperform by RBC Capital
Dow Jones · 03/15 16:59
aTyr Pharma Price Target Cut to $16.00/Share From $19.00 by RBC Capital
Dow Jones · 03/15 16:59
RBC Capital Maintains Outperform on aTyr Pharma, Lowers Price Target to $16
Benzinga · 03/15 16:49
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)
TipRanks · 03/15 10:50
aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Dow Jones · 03/15 10:30
Buy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial Footing
TipRanks · 03/15 10:25
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
Benzinga · 03/15 10:20
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023
ATyr Pharma reported earnings per share of -25 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. ATyr Pharmaceutical's earnings were below the analyst estimate for EPS of -24 cents. The company reported results for the last quarter of 2013.
Investorplace · 03/15 00:56
Recap: aTyr Pharma Q4 Earnings
ATyr Pharma is expected to report its Q4 earnings on March 14. The company missed its earnings estimate by $0.25. Revenue was down $10.39 million from the same period last year. The stock is down 4.0% in the last day.
Benzinga · 03/14 20:15
aTyr Pharma Q4 2023 GAAP EPS $(0.25) Misses $(0.24) Estimate
Benzinga · 03/14 20:14
More
Webull provides a variety of real-time LIFE stock news. You can receive the latest news about Atyr Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LIFE
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).